Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BHC NASDAQ:REGN NYSE:SNAP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHCBausch Health Cos$4.77-1.7%$5.15$4.57▼$8.69$1.79B0.422.12 million shs114,950 shsREGNRegeneron Pharmaceuticals$658.94-0.6%$644.42$541.00▼$821.11$69.67B0.24859,648 shs34,294 shsSNAPSnap$4.64-0.5%$5.29$3.81▼$10.41$7.83B1.0549.52 million shs2.39 million shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHCBausch Health Cos+1.68%+0.83%-3.96%-14.52%-24.49%REGNRegeneron Pharmaceuticals-0.22%+2.04%+8.32%-12.23%+16.79%SNAPSnap-0.43%-1.79%-10.97%-16.81%-48.80%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHCBausch Health Cos$4.77-1.7%$5.15$4.57▼$8.69$1.79B0.422.12 million shs114,950 shsREGNRegeneron Pharmaceuticals$658.94-0.6%$644.42$541.00▼$821.11$69.67B0.24859,648 shs34,294 shsSNAPSnap$4.64-0.5%$5.29$3.81▼$10.41$7.83B1.0549.52 million shs2.39 million shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHCBausch Health Cos+1.68%+0.83%-3.96%-14.52%-24.49%REGNRegeneron Pharmaceuticals-0.22%+2.04%+8.32%-12.23%+16.79%SNAPSnap-0.43%-1.79%-10.97%-16.81%-48.80%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHCBausch Health Cos 1.80Reduce$8.0067.82% UpsideREGNRegeneron Pharmaceuticals 2.70Moderate Buy$787.6719.54% UpsideSNAPSnap 2.22Hold$7.4861.39% UpsideCurrent Analyst Ratings BreakdownLatest REGN, SNAP, and BHC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/13/2026SNAPSnap UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$7.00 ➝ $5.007/9/2026REGNRegeneron Pharmaceuticals Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$855.00 ➝ $854.007/8/2026REGNRegeneron Pharmaceuticals Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$788.00 ➝ $730.007/8/2026SNAPSnap DA DavidsonSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$5.007/8/2026SNAPSnap The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$7.00 ➝ $6.007/7/2026SNAPSnap UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$5.007/7/2026REGNRegeneron Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetSector Perform$707.00 ➝ $696.007/7/2026REGNRegeneron Pharmaceuticals BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$185.007/7/2026REGNRegeneron Pharmaceuticals Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$778.00 ➝ $769.007/7/2026SNAPSnap Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$7.00 ➝ $5.007/6/2026REGNRegeneron Pharmaceuticals HSBCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$990.00 ➝ $880.00(Data available from 7/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHCBausch Health Cos$10.27B0.17$7.22 per share0.66$1.02 per share4.67REGNRegeneron Pharmaceuticals$14.34B4.86$41.63 per share15.83$295.66 per share2.23SNAPSnap$5.93B1.32N/AN/A$1.33 per share3.48Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHCBausch Health Cos$157M-$3.24N/A1.31N/A-11.47%-2,922.77%5.63%7/29/2026 (Estimated)REGNRegeneron Pharmaceuticals$4.50B$41.0416.0615.821.4729.65%13.16%10.17%7/30/2026 (Estimated)SNAPSnap-$460.49M-$0.24N/A66.21N/A-6.72%-18.92%-5.44%8/3/2026 (Estimated)Latest REGN, SNAP, and BHC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/3/2026Q2 2026SNAPSnap-$0.1193N/AN/AN/A$1.54 billionN/A7/30/2026Q2 2026REGNRegeneron Pharmaceuticals$10.40N/AN/AN/A$3.81 billionN/A7/29/2026Q2 2026BHCBausch Health Cos$0.96N/AN/AN/A$2.56 billionN/A5/6/2026Q1 2026SNAPSnap$0.09-$0.05-$0.14-$0.05$1.53 billion$1.53 billion4/29/2026Q1 2026BHCBausch Health Cos$0.81$0.78-$0.03-$3.76$2.37 billion$2.46 billion4/29/2026Q1 2026REGNRegeneron Pharmaceuticals$8.91$9.47+$0.56$6.75$3.48 billion$3.61 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBHCBausch Health CosN/AN/AN/AN/AN/AREGNRegeneron Pharmaceuticals$3.760.57%N/A9.16%N/ASNAPSnapN/AN/AN/AN/AN/ALatest REGN, SNAP, and BHC DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/29/2026REGNRegeneron Pharmaceuticalsquarterly$0.940.58%5/20/20265/20/20266/4/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHCBausch Health Cos54.681.320.97REGNRegeneron Pharmaceuticals0.063.572.96SNAPSnap1.673.533.53Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHCBausch Health Cos78.65%REGNRegeneron Pharmaceuticals83.31%SNAPSnap47.52%Insider OwnershipCompanyInsider OwnershipBHCBausch Health Cos20.67%REGNRegeneron Pharmaceuticals6.97%SNAPSnapN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHCBausch Health Cos20,300374.03 million296.72 millionOptionableREGNRegeneron Pharmaceuticals15,410105.72 million98.35 millionOptionableSNAPSnap5,2611.69 billionN/AOptionableREGN, SNAP, and BHC HeadlinesRecent News About These CompaniesSnap (SNAP) Beats Stock Market Upswing: What Investors Need to KnowJuly 9, 2026 | zacks.comBenchmark Maintains a Hold Rating on Snap Inc (SNAP) Despite SPECS ReleaseJuly 9, 2026 | finance.yahoo.comSnap Schedules 2026 Virtual Shareholder Meeting Under Founder ControlJuly 9, 2026 | tipranks.comSnap Inc. Announces Date of Second Quarter 2026 Results Conference CallJuly 9, 2026 | businesswire.comSnap (NYSE:SNAP) Coverage Initiated by Analysts at DA DavidsonJuly 8, 2026 | marketbeat.comSnap (NYSE:SNAP) Given New $6.00 Price Target at The Goldman Sachs GroupJuly 8, 2026 | marketbeat.comSnap (NYSE:SNAP) Price Target Cut to $5.00 by Analysts at Wells Fargo & CompanyJuly 7, 2026 | americanbankingnews.comWells Fargo & Company Has Lowered Expectations for Snap (NYSE:SNAP) Stock PriceJuly 7, 2026 | marketbeat.comSnap Inc. (NYSE:SNAP) Receives Consensus Rating of "Hold" from AnalystsJuly 5, 2026 | americanbankingnews.comSnap Inc. (NYSE:SNAP) Given Consensus Recommendation of "Hold" by BrokeragesJuly 5, 2026 | marketbeat.comSnap (SNAP) Faces Lawsuit Over Claims Snapchat Enabled Grooming Of MinorsJuly 4, 2026 | finance.yahoo.comUnpacking Q1 Earnings: Snap (NYSE:SNAP) In The Context Of Other Social Networking StocksJuly 3, 2026 | finance.yahoo.comAssenagon Asset Management S.A. Reduces Holdings in Snap Inc. $SNAPJuly 2, 2026 | marketbeat.comMeta Platforms vs. Snap: Comparing Revenue Scale and Recent TrajectoriesJune 28, 2026 | fool.comSnap Inc. (SNAP) Launches Specs Augmented-Reality GlassesJune 27, 2026 | insidermonkey.comSnap (SNAP) Faces Major Lawsuit Over Child Safety And Online Grooming RisksJune 26, 2026 | finance.yahoo.comSnap: 4 Independent Catalysts, One Cheap Options BetJune 25, 2026 | seekingalpha.comSnap sued over rape of minor who connected to adult attacker on SnapchatJune 25, 2026 | nypost.comNSnap Inc. $SNAP Shares Bought by SG Americas Securities LLCJune 25, 2026 | marketbeat.comSnap Inc. $SNAP Stock Position Trimmed by Hsbc Holdings PLCJune 25, 2026 | marketbeat.comSnap (SNAP) Advances While Market Declines: Some Information for InvestorsJune 24, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeREGN, SNAP, and BHC Company DescriptionsBausch Health Cos NYSE:BHC$4.77 -0.08 (-1.71%) As of 10:19 AM Eastern This is a fair market value price provided by Massive. Learn more.Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.Regeneron Pharmaceuticals NASDAQ:REGN$658.94 -4.15 (-0.63%) As of 10:19 AM Eastern This is a fair market value price provided by Massive. Learn more.Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.Snap NYSE:SNAP$4.64 -0.03 (-0.54%) As of 10:19 AM Eastern This is a fair market value price provided by Massive. Learn more.Snap Inc. operates as a technology company in North America, Europe, and internationally. The company offers Snapchat, a visual messaging application with various tabs, such as camera, visual messaging, snap map, stories, and spotlight that enable people to communicate visually through short videos and images. It also provides Spectacles, an eyewear product that connects with Snapchat and captures photos and video from a human perspective; and advertising products, including AR ads and Snap ads comprises a single image or video ads, collection ads, dynamic ads, story ads, and commercials. The company was formerly known as Snapchat, Inc. and changed its name to Snap Inc. in September 2016. Snap Inc. was founded in 2010 and is headquartered in Santa Monica, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Baggage Claim: Apollo’s $7.7 Billion Bid to Acquire easyJet The SK Hynix IPO and 2027’s AI Memory Squeeze Why Welltower's Growth Story Might Outrun Its Rich Valuation Why Micron Is Doubling Down While the HBM Shortage Persists AMD's 5C Deal Positions It as a Direct NVIDIA Rival China's Helium Ban Could Reshape the AI Supply Chain Fission for Profits: Unlocking America’s Uranium Vault The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
